Actualités
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
The United States market has experienced a flat week but has shown significant growth over the past year with a 27% increase, and earnings are anticipated to grow by 17% annually. In this context, identifying stocks that may be trading below their estimated value can offer opportunities for investors seeking to capitalize on potential future gains.
FEATURE Stock futures pointed higher Friday as investors remained cautiously optimistic a deal to end the stalemate between the U.S. and Iran could be reached. These stocks were moving in premarket trading: Estee Lauder rose 10%.
Merck has had an impressive run over the past six months as its shares have beaten the S&P 500 by 6.8%. The stock now trades at $113.99, marking a 20% gain. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Agenus' shares slide after weak Q1 results, but BOT/BAL phase III progress, survival data and Zydus backing keep long-term growth hopes alive.
Exelixis (EXEL) is back in the spotlight after announcing a clinical development collaboration with Merck to test zanzalintinib plus subcutaneous Keytruda in the planned phase 3 STELLAR-316 colorectal cancer trial. See our latest analysis for Exelixis. For context, Exelixis shares trade at US$49.90, with a 1 month share price return of 14.42% and a year to date share price return of 14.50%. The 3 year total shareholder return of 158.21% points to strong longer term momentum that recent...
LLY's booming GLP-1 franchise and expanding pipeline strengthen its edge over Merck despite rising competition and pricing pressure.
Eisai’s updated analyst model now points to a fair value price target of ¥5,076.92, compared with the prior ¥5,009.23, giving you a fresh reference point for how the stock is being framed today. Bullish and bearish analysts are reading this shift differently, with some seeing the new target as confirmation that the existing case still holds, and others viewing the change as a sign that potential upside could be more limited if the company simply tracks current assumptions. As you read on, you...
Over the last 7 days, the United States market has remained flat, yet it has seen an impressive 27% increase over the past year with earnings projected to grow by 17% per annum in the coming years. In this context of robust growth expectations, dividend stocks that offer stability and consistent income can be attractive options for investors seeking to capitalize on these favorable conditions.
The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) has built its reputation on paying reliable, growing quarterly distributions to income investors, and the latest data confirms why holders trust the fund. SCHD paid $0.2569 per share on March 30, 2026, continuing an uninterrupted quarterly schedule that stretches back to 2011. For retirees and dividend-growth investors weighing ... Why retirees are banking on SCHD’s 15-year unbroken dividend streak
Exelixis teams up with Merck to advance zanzalintinib in a phase III colorectal cancer study, expanding its pipeline beyond Cabometyx.
Earlier this week, Merck announced that its pivotal Phase 3 TroFuse-005 trial showed sacituzumab tirumotecan significantly improved overall and progression-free survival versus chemotherapy in certain patients with advanced or recurrent endometrial cancer, also meeting a key secondary endpoint of objective response rate with no new safety concerns. This is the first global Phase 3 study in this setting where an antibody-drug conjugate outperformed chemotherapy on both survival measures,...
New 25-strain Prevnar candidate moves into final-stage testing after strong infant trial results against severe pneumonia strain.
Shares of biotech company Regeneron (NASDAQ:REGN) fell 10.5% in the afternoon session after its experimental cancer treatment failed to meet the main goal in a late-stage study for patients with a type of advanced skin cancer.
PFE bets on Padcev, biosimilars and late-stage pipeline candidates to drive long-term oncology growth amid pressure on legacy drugs.
The next-generation version of Pfizer's $6 billion pneumococcal vaccine franchise topped its predecessor in a midstage study.
Merck (NYSE:MRK) reported positive global Phase 3 results from the TroFuse-005 trial of its antibody-drug conjugate sacituzumab tirumotecan in advanced or recurrent endometrial cancer. The study showed statistically significant improvement in both overall survival and progression-free survival, a first for an antibody-drug conjugate in this setting. The data could support major regulatory filings and introduce a new treatment option in an area with meaningful unmet medical need. For...
REGN teams up with Parabilis in a potential $2.2B deal to develop Antibody-Helicon Conjugates targeting hard-to-treat cancers.
Eli Lilly and Novo Nordisk are accelerating global obesity pill launches as rising GLP-1 demand puts weight-loss ETFs in focus.
MRK's investigational TROP2-directed ADC, sac-TMT, achieves key survival goals in a phase III endometrial cancer study.
Immunic Inc (NASDAQ:IMUX, FRA:10VA), a late-stage biotechnology company developing oral therapies for neurologic diseases, said it has appointed biopharmaceutical veteran Michael Bonney as chair of its board of directors. Bonney brings more than three decades of industry experience, including...
Merck’s analyst fair value estimate has shifted from US$124.88 to US$129.74 per share, providing an updated reference point for where some on the Street think the stock should trade. That change comes alongside recent research on the Terns deal, oncology pipeline updates, and fresh coverage initiations. Together, these developments help frame how analysts are weighing growth potential against execution and competitive risks. As you read on, you will see what is driving this evolving story and...
Regeneron stock sinks as fianlimab Phase 3 trial fails to meet primary endpoint. But RBC continues to see significant upside in REGN shares from here.
REGN's melanoma combo misses the primary endpoint in a phase III study despite longer median PFS versus Keytruda monotherapy.
Shares of Regeneron Pharmaceuticals are down about 11%, dragging the Nasdaq composite, after the company’s experimental melanoma drug failed a pivotal clinical trial. The company said that its drug fianlimab, when combined with an approved cancer drug, didn't keep patients’ disease from worsening significantly longer than Merck’s Keytruda.
Regeneron Pharmaceuticals stock crashed Monday after its experimental melanoma treatment failed in Phase 3 testing.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN), the US biotech group, fell premarket trading on Monday after its most closely watched clinical trial of the year delivered a statistical miss that has prompted a wave of analyst downgrades. The company disclosed on Friday that its phase 3 trial of...
The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ambitions of hitting $70 billion in annual sales next decade.
A late-stage trial evaluating Regeneron’s fianlimab, a skin cancer drug, fails to meet its primary endpoint.